Melissa R. Junttila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Melissa R. Junttila has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Jukka Westermarck
Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
2 shared publications - Anna A. Sablina
VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium
1 shared publication Hannu Haapasalo
Department of Pathology, Centre for Laboratory Medicine, Tampere University Hospital, 33520 Tampere, Finland
1 shared publicationJuergen Kast
The Biomedical Research Centre, University of British Columbia, Vancouver, Canada
1 shared publicationKaisa Teittinen
Institute of Medical Technology, University of Tampere and Centre for Laboratory Medicine, Tampere University Hospital, 33520 Tampere, Finland
1 shared publication- Kirsi Ketola
Institute of Biomedicine, University of Eastern Finland, 70210, Kuopio, Finland
1 shared publication
Latest Publications
- 1 April 2009
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (7) , 2870-2877
PME-1 Protects Extracellular Signal-Regulated Kinase Pathway Activity from Protein Phosphatase 2A–Mediated Inactivation in Human Malignant Glioma
Extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase pathway activity is regulated by the antagonist function of activating kinases and inactivating protein phosphatases. Sustained ERK pathway activity is commonly observed in human malignancies; however, the mechanisms by which the pathway is protected from phosphatase-mediated inactivation in the tumor tissue remain obscure. Here, we show that methylesterase PME-1–mediated inhibition of the protein phosphatase 2A promotes basal ERK pathway activity and is required for efficient growth factor response. Mechanistically, PME-1 is shown to support ERK pathway signaling upstream of Raf, but downstream of growth factor receptors and protein kinase C. In malignant gliomas, PME-1 expression levels correlate with both ERK activity and cell proliferation in vivo. Moreover, PME-1 expression significantly correlates with disease progression in human astrocytic gliomas (n = 222). Together, these observations identify PME-1 expression as one mechanism by which ERK pathway activity is maintained in cancer cells and suggest an important functional role for PME-1 in the disease progression of human astrocytic gliomas. [Cancer Res 2009;69(7):2870–7]
- 1 April 2009
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (7) , 2870-2877
PME-1 Protects Extracellular Signal-Regulated Kinase Pathway Activity from Protein Phosphatase 2A–Mediated Inactivation in Human Malignant Glioma
Extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase pathway activity is regulated by the antagonist function of activating kinases and inactivating protein phosphatases. Sustained ERK pathway activity is commonly observed in human malignancies; however, the mechanisms by which the pathway is protected from phosphatase-mediated inactivation in the tumor tissue remain obscure. Here, we show that methylesterase PME-1–mediated inhibition of the protein phosphatase 2A promotes basal ERK pathway activity and is required for efficient growth factor response. Mechanistically, PME-1 is shown to support ERK pathway signaling upstream of Raf, but downstream of growth factor receptors and protein kinase C. In malignant gliomas, PME-1 expression levels correlate with both ERK activity and cell proliferation in vivo. Moreover, PME-1 expression significantly correlates with disease progression in human astrocytic gliomas (n = 222). Together, these observations identify PME-1 expression as one mechanism by which ERK pathway activity is maintained in cancer cells and suggest an important functional role for PME-1 in the disease progression of human astrocytic gliomas. [Cancer Res 2009;69(7):2870–7]
- 1 March 2008
- Published by Taylor & Francis in Cell Cycle
- Vol. 7 (5) , 592-596
Mechanisms of MYC stabilization in human malignancies
MYC is a pleiotropic transcription factor that has been linked to a diverse range of cellular functions, such as cell cycle regulation, proliferation, growth, differentiation and metabolism. Not surprisingly, aberrant MYC signaling has been observed in human cancers and MYC has been demonstrated to promote cell transformation and tumor progression. Here we discuss recent discoveries that have expanded our knowledge of MYC protein stability. In particular we focus on mechanisms that might explain the increased stability of MYC often observed in human cancers and cell lines. We also summarize our recent characterization of Cancerous inhibitor of PP2A (CIP2A(/KIAA1524)) as a protein that inhibits PP2A-mediated MYC dephosphorylation and proteolytic degradation. Finally, we discuss the potential relevance of mechanisms that regulate MYC stability for tumor formation in the context of cancer therapy.
- 1 March 2008
- Published by Taylor & Francis in Cell Cycle
- Vol. 7 (5) , 592-596
Mechanisms of MYC stabilization in human malignancies
MYC is a pleiotropic transcription factor that has been linked to a diverse range of cellular functions, such as cell cycle regulation, proliferation, growth, differentiation and metabolism. Not surprisingly, aberrant MYC signaling has been observed in human cancers and MYC has been demonstrated to promote cell transformation and tumor progression. Here we discuss recent discoveries that have expanded our knowledge of MYC protein stability. In particular we focus on mechanisms that might explain the increased stability of MYC often observed in human cancers and cell lines. We also summarize our recent characterization of Cancerous inhibitor of PP2A (CIP2A(/KIAA1524)) as a protein that inhibits PP2A-mediated MYC dephosphorylation and proteolytic degradation. Finally, we discuss the potential relevance of mechanisms that regulate MYC stability for tumor formation in the context of cancer therapy.